TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Melanomas that arise on chronically sun damaged skin and have pathologic evidence of solar elastosis~* History of primary mucosal or acral/lentiginous melanoma~* Histologically documented stage IV metastatic melanoma~* ECOG performance status 0,1, or 2~* Estimated life expectancy of 6 months or greater~* Age 18 years or older~* Creatinine \< 1.5 x ULN~* ANC \> 1500 ul~* Platelets \> 100,000 ul~* Total bilirubin, AST, and ALT \< 2 x ULN~* Amylase and lipase \< 1.5 x ULN~* C-kit mutation documented from either primary or metastatic tumor site~* \> 4 weeks from prior chemotherapy or investigational drug~* At least one measurable site of disease as defined by at least 1 cm in greatest dimension~Exclusion Criteria:~* Severe and/or uncontrolled medical disease~* Pregnant or nursing mothers~* Any other significant medical, surgical, or psychiatric condition that my interfere with compliance~* Patient is \< 5 years free of another primary malignancy except: basal cell skin cancer or a cervical carcinoma in situ~* Concurrent treatment with Warfarin~* Prior treatment with c-kit inhibitor~* Patient with Grade III/IV cardiac problems as defined by NYHA criteria~* No H2 blockers or proton pump inhibitors~* Known brain metastasis~* Known chronic liver disease~* Known diagnosis of HIV infection~* Previous radiotherapy to \> 25% of the bone marrow~* Major surgery within 2 weeks prior to study entry~* Patient has received any other investigational agent within 28 days of first study drug dosing~* Chemotherapy within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Imatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization~* Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization~* Candidate for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis~* History of drug-induced psoriasis~* Clinically significant flare of psoriasis during the 12 weeks prior to randomization~* Concurrent or recent use of any biologic agent~* Received systemic psoriasis therapy \[such as psoralen and ultraviolet A (PUVA) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study~* Have participated in any study with interleukin-17 (IL-17) antagonists, including Ixekizumab~* Serious disorder or illness other than plaque psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg Ixekizumab Auto-Injector (Type: EXPERIMENTAL): Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
- 80 mg Ixekizumab Prefilled Syringe (Type: EXPERIMENTAL): Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18-65~* Diagnosis of schizophrenia, any subtype, or schizoaffective disorder, any sub-type~* Body mass index \> 30 Kg/m2 or \>27 Kg/m2 with other risk factors (HTN, Lipid abnormalities)~* Well established compliance with outpatient medications.~* Maintained on a stable dose of olanzapine for at least one month.~Exclusion Criteria:~* Serious medical or neurological illness (unstable cardiac disease, malignancy, liver or renal impairment, etc.)~* Current substance abuse~* Psychiatrically unstable, which is defined as a score on the CGI's severity of illness question of 5 or greater or a baseline Total PANSS score \> 75~* Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile~* Serious suicidal or homicidal risk within the past three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): aripiprazole 15mg/day
- placebo (Type: PLACEBO_COMPARATOR): matched placebo for aripiprazole 15mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females diagnosed with type 1 diabetes mellitus for at least 24 months~* Current usage of subcutaneous insulin pump treatment~* Age 18-65 years~* C-peptide level \< 0.5 ng/ml~* Willingness to follow all study procedures, including attending all clinic visits~* Subject has provided informed consent and has signed and dated an informed consent form before any trial-related activities~Exclusion Criteria:~* Pregnant and/ or Lactating: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.~* HbA1c \>10.0%~* Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)~* Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum bilirubin of over 2.0.~* Hematocrit of less than or equal to 34%~* Congestive heart failure, NYHA class II, III or IV~* History of coronary artery disease~* Active foot ulceration~* History of a cerebrovascular accident~* Active alcohol abuse or substance abuse~* Active malignancy, except basal cell or squamous cell skin cancers~* Major surgical operation within 30 days prior to screening~* Seizure disorder~* Current administration of oral or parenteral corticosteroids~* Use of an investigational drug within 30 days prior to screening~* Bleeding disorder, treatment with warfarin, or platelet count below 50,000~* Proliferative or severe non-proliferative retinopathy~* Gastroparesis~* Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)~* Insulinoma~* Allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products.~* Glycogen storage disease~* Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen~* Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.~* Any reason the principal investigator deems exclusionary

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-Pump™ (glucagon infusion) (Type: EXPERIMENTAL): G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
- Novo Nordisk GlucaGen® (Type: ACTIVE_COMPARATOR): Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV-1 infected~* CD4 count 250 cells/mm3 or greater within 30 days of study entry~* The following laboratory values obtained within 30 days prior to study entry: absolute neutropil count \>= 750/mm3; hemoglobin \>= 8.0 g/dL; platelet count \>= 50,000/mm3; calculated creatinine clearance (Cockcroft-Gault formula) \> 60 mL/min; AST(SGOT) and ALT(SGPT) \< 5 x ULN; total bilirubin \< 1.5 X ULN.~* Pregnant with a viable fetus at 28 to 38 weeks gestation at study entry.~* Willing to give birth to baby in a hospital or clinic~* Written informed consent from parent or guardian, if applicable~Exclusion Criteria for Mothers:~* Any ART, including single-dose NVP, prior to study entry. Mothers who receive ZDV monotherapy prior to labor under the supervision of the site investigator are not excluded.~* Known allergy or sensitivity to study drugs or their formulations~* Current drug or alcohol abuse that may interfere with the study~* Serious illness requiring systemic treatment or hospitalization. Participants who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.~* Hepatitis B surface antigen positive within 180 days prior to study entry~* Active tuberculosis infection requiring treatment~* Prior enrollment in this study~* Expect to use ART, except ZDV monotherapy, prior to onset of labor~* Expect to use ART other than study medications from delivery to 9 weeks postpartum

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 7-day 3TC/ZDV (Type: EXPERIMENTAL): SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
- 21-day 3TC/ZDV (Type: EXPERIMENTAL): SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
- 7-day FTC/TDF (Type: EXPERIMENTAL): SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
- 21-day FTC/TDF (Type: EXPERIMENTAL): SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
- 7-day LPV/r (Type: EXPERIMENTAL): SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
- 21-day LPV/r (Type: EXPERIMENTAL): SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Physical Activity Among Sedentary Older Adults:What, Where, When, and With Whom

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sedentary adults, who own an iphone with step-tracking capabilities (5s or later).~* Participants must be fit enough to walk for at least 20 minutes at a time.~Exclusion Criteria:~* Cognitive impairment~* A recent (within the past 6 months) cardiovascular event, or fall.~* A doctor has advised them not to walk~* Anyone who already exercises regularly: walks for exercise more than 30 minutes per day, or does other forms of exercise 150 minutes per week or more, will be excluded.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- App Control Condition (Type: EXPERIMENTAL): The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
- App Experimental condition (Type: EXPERIMENTAL): The experimental condition will set step goals and have the schedule, map, and social components for 1 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. comply with Leber hereditary optic neuropathy diagnostic criteria.~2. in patients with informed consent, voluntary participation.~3. signed informed consent.~4. 8 ≤ Age ≤ 60 years old, good health, the patient can tolerate local anesthesia surgery.~5. to comply with doctor's instructions, can in the time of referral.~Exclusion Criteria:~1. Cardiopulmonary and renal function in severe weakness, cancer, a variety of bleeding disorders, acute sensing disease, high fever, high fever disease, women during pregnancy, heart disease, such as post-operative recovery period.~2. Are participating in other clinical studies of patients.~3. Patients with mental disorders.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- rAAV2-ND4 (Type: EXPERIMENTAL): injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female adults~2. Aged 65 to 85 years~Exclusion Criteria:~1. Proven or suspected prior episode of Clostridium difficile associated diarrhea~2. Unstable chronic medical condition~3. Disease requiring significant change in therapy or hospitalization for worsening disease within 8 weeks before receipt of study vaccine~4. Serious chronic medical disorders~5. Bleeding diathesis or condition associated with prolonged bleeding time that may contraindicate intramuscular injection~6. Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components~7. Subjects with congenital or acquired immunodeficiency disorders~8. Subjects with rheumatologic disorders or other illnesses requiring chronic treatment with known immunosuppressant medications~9. Active or treated leukemia or lymphoma or bone marrow disorder~10. Residence in a nursing home or other long-term care facility, or requirement for semiskilled nursing care or assisted living~11. Abnormality in screening hematology and/or blood chemistry laboratory values

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose C. difficile Vaccine (accelerated schedule) (Type: EXPERIMENTAL): None
- High-dose C. difficile Vaccine (accelerated schedule) (Type: EXPERIMENTAL): None
- Placebo (accelerated schedule) (Type: PLACEBO_COMPARATOR): None
- Low-dose C. difficile Vaccine (non-accelerated schedule) (Type: EXPERIMENTAL): None
- High-dose C. difficile Vaccine (non-accelerated schedule) (Type: EXPERIMENTAL): None
- Placebo (non-accelerated schedule) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received EYLEA for AMD~Exclusion Criteria:~* Patients who have already received EYLEA

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fertile women between age of 20 and 49~* Patients with cervical intraepithelial neoplasia 1(CIN1)~* HPV(Human Papilloma Virus) positive(+)~* White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 10\^6/L~* AST(Aspartate Aminotransferase) no less than 4 times higher than normal ALT(Alanine Aminotransferase) no less than 4 times higher than normal~* Normal for EKG(Electrocardiography) and no active disease detected trough chest X-ray~* Be informed of the nature of the study and will give written informed consent~Exclusion Criteria:~* Malignant tumor in any organ other than cervical intraepithelial neoplasia~* Active liver disease, immune disorder and severe renal failure~* Leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant allergic disease(mild allergic symptom not required medicine excluded)~* Diagnosed diabetes~* Taking any of followings affecting immunological reaction within 7 days (Glucocorticoid, vitamins, health food and oriental medicine etc)~* Pregnancy and breastfeeding~* Registered in other clinical trials~* Patients whom the investigator considers inappropriate to participate in the study

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Poly-gamma Glutamic Acid (Type: EXPERIMENTAL): Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presence of a first or second pregnancy.~2. Gestation between 16 to 30 weeks inclusive at first booking as determined by symphysio-fundal measurements.~3. Provision of informed consent to join the trial.~4. Residence in the study area and intention to stay in the area for the duration of the pregnancy.~Exclusion Criteria:~1. Absence of informed consent.~2. An intention to leave the study area before delivery.~3. A history of sensitivity to sulphonamides.~4. Clinical AIDS or known HIV positivity.~5. Presence of any systemic illness likely to interfere with interpretation of the results of the trial.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- IPTp with SP (Type: ACTIVE_COMPARATOR): Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
- IST using RDTs (Type: EXPERIMENTAL): Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete